Clinical advances in periodontics · 2012
Amlodipine-Induced Gingival Overgrowth in a Patient With Uncontrolled Type 2 Diabetes Mellitus With Hypercholesterolemia: A Case Report.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Smitha K
Аннотация
INTRODUCTION: Gingival overgrowth, with its potential cosmetic implications and for providing new niches for the growth of microorganisms, is a serious concern for both patients and clinicians. Amlodipine is a comparatively new calcium channel blocker and is being used with increasing frequency in the management of hypertension and angina. Although amlodipine is considered a safe drug, it may induce gingival overgrowth in some individuals.
CASE PRESENTATION: A rare case of amlodipine-induced gingival overgrowth in a 60-year-old Indian woman who was on amlodipine for 3 years and subsequent periodontal management of the overgrowth is reported here. The patient did not have any gingival overgrowth for 2 years despite the fact that she was taking amlodipine, but she developed the gingival overgrowth 9 months before her initial visit, coincident with uncontrolled diabetes mellitus and use of a cholesterol-lowering drug. She was treated with drug substitution for the systemic condition and surgical treatment for the overgrowth. She was followed up for 1 year, regularly.
CONCLUSION: We speculate that overgrowth could have been triggered by uncontrolled type 2 diabetes mellitus and by altered pharmacokinetics of amlodipine resulting from the drug interaction of amlodipine with a cholesterol-lowering drug.
CASE PRESENTATION: A rare case of amlodipine-induced gingival overgrowth in a 60-year-old Indian woman who was on amlodipine for 3 years and subsequent periodontal management of the overgrowth is reported here. The patient did not have any gingival overgrowth for 2 years despite the fact that she was taking amlodipine, but she developed the gingival overgrowth 9 months before her initial visit, coincident with uncontrolled diabetes mellitus and use of a cholesterol-lowering drug. She was treated with drug substitution for the systemic condition and surgical treatment for the overgrowth. She was followed up for 1 year, regularly.
CONCLUSION: We speculate that overgrowth could have been triggered by uncontrolled type 2 diabetes mellitus and by altered pharmacokinetics of amlodipine resulting from the drug interaction of amlodipine with a cholesterol-lowering drug.